APA (7th ed.) Citation

Capehorn, M., Catarig, A., Furberg, J., Janez, A., Price, H., Tadayon, S., . . . Marre, M. (2020). Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes & metabolism, 46(2), 100-109. https://doi.org/10.1016/j.diabet.2019.101117

Chicago Style (17th ed.) Citation

Capehorn, M.S, A.-M Catarig, J.K Furberg, A. Janez, H.C Price, S. Tadayon, B. Vergès, and M. Marre. "Efficacy and Safety of Once-weekly Semaglutide 1.0 Mg Vs Once-daily Liraglutide 1.2 Mg as Add-on to 1–3 Oral Antidiabetic Drugs in Subjects with Type 2 Diabetes (SUSTAIN 10)." Diabetes & Metabolism 46, no. 2 (2020): 100-109. https://doi.org/10.1016/j.diabet.2019.101117.

MLA (9th ed.) Citation

Capehorn, M.S, et al. "Efficacy and Safety of Once-weekly Semaglutide 1.0 Mg Vs Once-daily Liraglutide 1.2 Mg as Add-on to 1–3 Oral Antidiabetic Drugs in Subjects with Type 2 Diabetes (SUSTAIN 10)." Diabetes & Metabolism, vol. 46, no. 2, 2020, pp. 100-109, https://doi.org/10.1016/j.diabet.2019.101117.